EP1128848A4 - A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers - Google Patents

A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers

Info

Publication number
EP1128848A4
EP1128848A4 EP99954757A EP99954757A EP1128848A4 EP 1128848 A4 EP1128848 A4 EP 1128848A4 EP 99954757 A EP99954757 A EP 99954757A EP 99954757 A EP99954757 A EP 99954757A EP 1128848 A4 EP1128848 A4 EP 1128848A4
Authority
EP
European Patent Office
Prior art keywords
staging
diagnosing
monitoring
novel method
treating gynecological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99954757A
Other languages
German (de)
French (fr)
Other versions
EP1128848A1 (en
Inventor
Roberto A Macina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1128848A1 publication Critical patent/EP1128848A1/en
Publication of EP1128848A4 publication Critical patent/EP1128848A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
EP99954757A 1998-10-05 1999-10-05 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers Withdrawn EP1128848A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10309398P 1998-10-05 1998-10-05
US103093P 1998-10-05
PCT/US1999/023252 WO2000020043A1 (en) 1998-10-05 1999-10-05 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers

Publications (2)

Publication Number Publication Date
EP1128848A1 EP1128848A1 (en) 2001-09-05
EP1128848A4 true EP1128848A4 (en) 2002-08-28

Family

ID=22293359

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99954757A Withdrawn EP1128848A4 (en) 1998-10-05 1999-10-05 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers

Country Status (4)

Country Link
EP (1) EP1128848A4 (en)
JP (1) JP2002526752A (en)
CA (1) CA2346326A1 (en)
WO (1) WO2000020043A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
GB0102562D0 (en) 2001-02-01 2001-03-21 Unilever Plc Cosmetic products for the reduction of sweat acidity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007857A1 (en) * 1996-08-19 1998-02-26 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999045147A1 (en) * 1998-03-05 1999-09-10 Diadexus Llc A novel method of detecting and monitoring endometrial and uterine cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7180198A (en) * 1996-11-12 1998-06-03 Incyte Pharmaceuticals, Inc. Human breast tumor-specific proteins
JP2002506437A (en) * 1997-06-09 2002-02-26 スミスクライン・ビーチャム・コーポレイション Novel method of detecting and treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007857A1 (en) * 1996-08-19 1998-02-26 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999045147A1 (en) * 1998-03-05 1999-09-10 Diadexus Llc A novel method of detecting and monitoring endometrial and uterine cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0020043A1 *
SHIINA H. ET AL.: "Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity on human prostatic carcinoma.", THE PROSTATE, vol. 32, no. 1, June 1997 (1997-06-01), pages 49 - 58, XP002203426 *

Also Published As

Publication number Publication date
EP1128848A1 (en) 2001-09-05
JP2002526752A (en) 2002-08-20
CA2346326A1 (en) 2000-04-13
WO2000020043A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
EP1105528A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1082459A4 (en) A novel method of diagnosing, monitoring, and staging lung cancer
EP1239874A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
HK1044816A1 (en) Method of diagnosing and monitoring malignant breast carcinomas
GB2340152B (en) Multiple string completion apparatus and method
AU6688598A (en) Method for diagnosing and staging prostate cancer
EP1131095A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
HU9902009D0 (en) Lamp and method of its operation
GB2344883B (en) Flame monitoring methods and apparatus
EP1267934A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1104486A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
AU4076399A (en) Gas well dewatering method and device
EP1107798A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1082460A4 (en) A novel method of diagnosing, monitoring, and staging prostate cancer
EP0918989A4 (en) Method of detecting gynecological carcinomas
AU2001268633A1 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer
GB9807051D0 (en) Monitoring arrangement and method
EP1128848A4 (en) A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers
EP1126877A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1117833A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
AU2001271621A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
GB9825583D0 (en) Pipe lining method
EP1053057A4 (en) Fiber panel manufacturing method and apparatus
EP1169066A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
EP1227841A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/395 A, 7C 12Q 1/00 B, 7C 12Q 1/68 B, 7G 01N 33/53 B, 7G 01N 33/567 B, 7G 01N 33/574 B, 7A 61K 51/10 B, 7A 61P 35/00 B, 7A 61K 47/48 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020712

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031013

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051129